Takeda

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen files Darzalex Faspro for rare disease light chain a...

Janssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal disease light chain (AL) amyloidosis.

News

Takeda agrees $2.3bn sale of Japanese consumer health unit

Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs.

News

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter.

News

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form of non-Hodgkin lymphoma (NHL), says NICE.

News

Takeda to make $200m loss after Novartis' dry-eye drug hits ...

Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing it to make a loss of $200 million this quarter.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

Janssen files Darzalex Faspro for rare disease light chain a...

Takeda agrees $2.3bn sale of Japanese consumer health unit

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Takeda to make $200m loss after Novartis' dry-eye drug hits ...

After Celgene deal, BMS shoots up pharma market cap rankings

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Takeda

Editor's Picks